Based on proteins which have a therapeutic effect. Biologics are complex, large molecule drugs

Biologics are part of what Syncona calls the “Second Wave” of technologies in healthcare and are dominated by large pharmaceutical companies.

Syncona targets innovative technologies in the space and our company Anaveon is a strong example of this.

Key facts*

£19m

value of biologics portfolio

2

Syncona Board seats

1

Clinical trial

Our Biologics portfolio companies

The biologics pipeline

Drug discovery Pre-clinical Clinical

Our domain areas

Syncona has deep domain expertise across four key therapeutic areas.

*Unless stated all financials at 31 March 2021